StockData
Coherus Oncology, Inc. logo

Coherus Oncology, Inc. (CHRS) stock analysis

CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3038% below fair value
$0.53−0.01 (-2.41%)

Close on Nov 13, 2026Market cap $81.19MP/E –Yield –

StockData Score

Prices as of Nov 13, 2026How the score works

Value2Growth2Performance1Health1Dividend0

Weak6 of 30 checks passed

Coherus Oncology passes 6 of the 30 checks behind our score; 15 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
2/6
Growth
2/6
Past performance
1/6
Financial health
1/6
Dividend
0/6

What stands out

  • Margin of safety over 20%

    The price is 38.4% below fair value, more than the 20% cushion we look for.

  • Trading below fair value

    The share price of $0.53 is below our fair value estimate of $0.85.

  • Earnings grew over 5 years

    Net income grew 4.9% a year on average over the last five fiscal years.

  • Growing faster than the industry

    Revenue grew 44.4% over the last twelve months; the Drugs median is 7.7%.

What to watch

  • Revenue growing under 10% a year

    Revenue grew -41.5% a year over the last three fiscal years, short of the 10% we look for.

  • Earnings growth not accelerating

    Net income grew -188% over the last twelve months, against a 5-year average of 4.9% a year.

  • Interest not well covered

    Operating income covers interest expense -15.5 times; we look for at least 5.

  • Elevated bankruptcy risk

    The Altman Z-score is -14.06; above 3 is the safe zone and below 1.8 the distress zone.

Valuation2/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B above the industry

    Coherus Oncology's price-to-book of 3.22 is above the Drugs median of 2.09.

  • Trading below fair value

    The share price of $0.53 is below our fair value estimate of $0.85.

  • Margin of safety over 20%

    The price is 38.4% below fair value, more than the 20% cushion we look for.

Growth2/6

  • Revenue growing under 10% a year

    Revenue grew -41.5% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings growth not accelerating

    Net income grew -188% over the last twelve months, against a 5-year average of 4.9% a year.

  • Growing faster than the industry

    Revenue grew 44.4% over the last twelve months; the Drugs median is 7.7%.

  • Guidance issued

    The latest outlook (by 2028 Revenues, Jan 13, 2026) was issued for the first time, so it neither adds nor takes away points.

  • Gross margin improving

    Gross margin was 69.8% over the last twelve months, against 66.3% a year earlier.

Past performance1/6

  • Return on equity

    Needs positive equity and five years of results.

  • Return on invested capital

    Needs operating income and invested capital.

  • Return on equity below the industry

    Coherus Oncology's return on equity of -241% is below the Drugs median of -57.0%.

  • Earnings grew over 5 years

    Net income grew 4.9% a year on average over the last five fiscal years.

  • Net margin below its 5-year average

    Net margin was -253% over the last twelve months, against a 5-year average of 37.6%.

  • Net margin below the industry

    Coherus Oncology's net margin of -253% is below the Drugs median of -53.5%.

Financial health1/6

  • Debt level

    Needs debt and equity figures.

  • Debt trend

    Needs a balance sheet from five years ago with positive equity.

  • Debt coverage

    Needs operating cash flow.

  • Interest not well covered

    Operating income covers interest expense -15.5 times; we look for at least 5.

  • Short-term assets cover short-term debts

    Current assets are 1.51 times current liabilities.

  • Elevated bankruptcy risk

    The Altman Z-score is -14.06; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

  • No dividend

    Coherus Oncology has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

Our estimate per share

$0.85

The share price is 38% below this estimate.

20%+ below
Near fair value
20%+ above
$0.53Price$0.85Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/B2.7×3.2×2.1×$0.4450%
P/S3.7×2.6×4.7×$1.2750%
Fair value$0.85100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Drugs median 25.0

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

High risk

Average value traded per day
$1.78M
Value traded per 1% price move
$308.30K

Downside

High risk

Typical loss in a bad month
35.7%
Volatility (annualized)
88%
Sharpe ratio, 1 year
-0.75
Beta to the S&P 500 (5Y)
1.37

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2011 to 2025

Gross margin

67.2%−24.8 pts over 5 years

Operating margin

-429.5%−462.4 pts over 5 years

Net margin

398.4%+370.6 pts over 5 years

See a number that looks wrong?